Disability News and Research

RSS

EU Joint Programming initiative to tackle neurodegenerative diseases

Leading researchers from across Europe will gather today in Stockholm to develop a European-wide research strategy to tackle neurodegenerative diseases such as Alzheimer's and Parkinson's Disease.

15 Apr 2010

Study: Atorvastatin may slow down MS progression

A UCSF-led study examining the impact of statins on the progression of multiple sclerosis found a lower incidence of new brain lesions in patients taking the cholesterol-lowering drug in the early stages of the disease as compared to a placebo.

15 Apr 2010

Genzyme presents 4-year follow-up data from Phase 2 MS trial at neurology meeting

Genzyme Corporation today reported four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial showing an estimated 71 percent of alemtuzumab treated patients remain free of clinically-active disease as much as three years after most patients received their last course of the investigational compound. The data were presented at the American Academy of Neurology annual meeting.

15 Apr 2010

GBS cases reduce following 2009 H1N1 vaccination: Research study

A new study finds that reports of a neurologic disease called Guillain-Barré syndrome have been low after 2009 H1N1 vaccination, according to a research study that will be presented as part of the late-breaking science program at the American Academy of Neurology's 62nd Annual Meeting in Toronto, April 10 - 17, 2010.

15 Apr 2010

People with disabilities may be unable to afford Medicare Advantage plan under healthcare provisions

The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010 are the most powerful developments in decades affecting healthcare coverage for people with disabilities, according to Allsup, a nationwide provider of Social Security disability representation and Medicare plan selection services.

15 Apr 2010

Potential new drug for treatment of MS to be presented at AAN Annual Meeting

Researchers from Mount Sinai School of Medicine will present several studies at the American Academy of Neurology Annual Meeting, including a potential new drug for the treatment of multiple sclerosis and surprising trends showing a reduction in the disease's severity. The meeting will take place April 10-17 in Toronto.

15 Apr 2010

Opexa Therapeutics presents key efficacy data on Tovaxin

Opexa Therapeutics, Inc., a company developing a novel T-cell therapy for multiple sclerosis, announced today that the Company presented key efficacy data at the American Academy of Neurology 62nd Annual Meeting held in Toronto, Canada.

15 Apr 2010

Study suggests patients with low-back pain may benefit from chiropractic treatment

Low-back pain sufferers can seek relief from any number of health professionals, orthopedists, physical therapists and osteopaths among them.

15 Apr 2010

Guardian examines Africa's health worker shortage

The Guardian's "Katine Chronicles" blog examines the global shortage of health workers. According to the U.K.'s Department for International Development (DfID), more than 50 countries have a "critical shortage" of health workers and Africa needs an additional 800,000 health workers by 2015.

15 Apr 2010

Articulinx closes $10M Series B financing round

Articulinx, Inc., a medical device company developing a novel minimally-invasive approach for the treatment of osteoarthritis, announced today the closing of a $10M Series B financing led by US Venture Partners (USVP).

15 Apr 2010

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.

13 Apr 2010

ACOEM awards CHAA Exemplary Practice Citation to URS Corporation

URS Corporation, a global engineering and construction firm serving both private and public sector organizations, has been awarded the Corporate Health Achievement Award (CHAA) Exemplary Practice Citation by the American College of Occupational and Environmental Medicine (ACOEM). URS Corporation received the citation for its outstanding efforts in promoting employee health, wellness, and safety.

13 Apr 2010

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

Biogen Idec and Elan Corporation, plc today announced 15 company-sponsored platform and poster presentations at the American Academy of Neurology's (AAN) 62nd Annual Meeting in Toronto, April 10 - 17, 2010. The AAN Annual Meeting is the world's largest gathering of neurologists.

13 Apr 2010

Antidepressants and mood stabilizers may benefit stroke victims

A study in rodents shows the growth of new neurons, also known as neurogenesis, lessens the severity of stroke and dramatically improves function following a stroke. The research, undertaken at the Buck Institute for Age Research, suggests that drugs shown to promote neurogenesis in rodents could have benefits for human stroke victims and that those drugs-which include antidepressants and mood stabilizers such as lithium-may be suitable for study in human clinical trials.

13 Apr 2010

Tailwind device that helps stroke survivors improve arm movement now available

The Tailwind, a new rehabilitation device that helps stroke survivors improve arm movement, even many years after their stroke, is now available on the eve of May as National Stroke Awareness Month. The exercise device empowers stroke survivors to become more independent and enables them to achieve the tasks of daily life.

13 Apr 2010

Uninsured migraine sufferers likely to get inadequate treatment: Neurology

People with no health insurance are less likely than the privately insured to receive proper treatment for their migraines, according to a study published in the April 13, 2010, print issue of Neurology, the medical journal of the American Academy of Neurology.

13 Apr 2010

Semel Institute for Neuroscience and Human Behavior awarded $14.9M for establishing new IPCN

The Semel Institute for Neuroscience and Human Behavior at UCLA has been awarded $14.9 million in American Recovery and Reinvestment Act funds to establish a center dedicated to interdisciplinary research on the role of genetic and environmental factors in neuropsychiatric and behavioral disorders.

13 Apr 2010

World first - newborn receives xenon gas in bid to prevent brain injury

In a world first, xenon gas has been successfully delivered to a newborn baby in a bid to prevent brain injury following a lack of oxygen at birth. This pioneering technique was developed by Professor Marianne Thoresen of the University of Bristol and carried out at St Michael’s Hospital, part of University Hospitals Bristol NHS Foundation Trust.

12 Apr 2010

Terrible tragedy for Alzheimer's suffering mother and family

In an bizarre situation a 31 year old Australian woman called Rebecca Doig, who gave birth to a healthy girl last week does not even remember giving birth to the child. The little girl called Emily has never been taken into her mother’s arms and it seems never will.

12 Apr 2010

Updated Safe Practices for Better Healthcare manual

To improve the quality and safety of healthcare in the United States, the National Quality Forum is releasing its updated manual Safe Practices for Better Healthcare. The 34 Safe Practices outlined in the manual are tools to prevent healthcare errors and address common issues like healthcare-associated infections, medication errors, surgical errors, and pressure ulcers

9 Apr 2010